Trombola 50 mg (Eltrombopag Olamine) Tablets

Introduction:

Trombola 50 mg, manufactured by Ziska Pharmaceuticals Ltd and supplied by Orio Pharma, is an advanced therapy designed for the treatment of thrombocytopenia (low platelet count) and severe aplastic anemia. Containing Eltrombopag Olamine, Trombola 50 mg is a thrombopoietin receptor agonist that stimulates the production of platelets in the bone marrow, helping to increase platelet counts and reduce the risk of bleeding in patients with chronic immune thrombocytopenia (ITP) and aplastic anemia. This medication offers a vital treatment option for patients who have not responded adequately to other therapies.

Manufacturing Excellence of Ziska Pharmaceuticals Ltd.:

Ziska Pharmaceuticals Ltd. is dedicated to producing high-quality pharmaceutical products that meet stringent international standards. The development of Trombola 50 mg reflects Ziska’s commitment to advancing hematological treatments through innovative research, rigorous quality control, and adherence to best manufacturing practices. Their focus on safety and efficacy ensures that Trombola 50 mg is a reliable and effective option for managing thrombocytopenia and aplastic anemia.

Mechanism of Action:

Trombola 50 mg contains Eltrombopag Olamine, a thrombopoietin receptor agonist that mimics the action of thrombopoietin, a natural hormone responsible for the production of platelets in the bone marrow. By binding to and activating the thrombopoietin receptor, Eltrombopag stimulates the proliferation and differentiation of megakaryocytes, the precursor cells that produce platelets. This increase in platelet production helps to elevate platelet counts in patients with chronic immune thrombocytopenia (ITP) and severe aplastic anemia, reducing the risk of bleeding and improving overall blood health.

Clinical Applications:

Trombola 50 mg is indicated for the treatment of:

• Chronic Immune Thrombocytopenia (ITP): Trombola 50 mg is used in adult and pediatric patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. It helps to increase platelet counts and reduce the risk of bleeding.
• Severe Aplastic Anemia: Trombola 50 mg is also indicated for the treatment of severe aplastic anemia in patients who have not responded adequately to immunosuppressive therapy.

Clinical studies have shown that Eltrombopag significantly increases platelet counts in patients with chronic ITP and aplastic anemia, making it a crucial option in the management of these conditions.

Dosage and Administration:

The recommended dosage of Trombola 50 mg varies depending on the patient’s condition, response to treatment, and platelet counts. For chronic ITP, the initial dose is typically 50 mg once daily, with adjustments made based on the patient’s platelet response. For severe aplastic anemia, the dosage may vary, and close monitoring is required. The tablets should be taken on an empty stomach, either one hour before or two hours after a meal. Patients should follow their healthcare provider’s instructions carefully and regularly monitor their platelet counts and liver function during treatment.

Benefits of Trombola 50 mg:

• Effective Platelet Production: Trombola 50 mg stimulates the production of platelets, helping to increase platelet counts and reduce the risk of bleeding in patients with chronic ITP and aplastic anemia.
• Targeted Therapy: By specifically targeting the thrombopoietin receptor, Trombola 50 mg provides a focused approach to treating thrombocytopenia and related conditions.
• Convenient Oral Administration: The once-daily oral dosing of Trombola 50 mg ensures ease of use and supports patient adherence to the treatment regimen.
• Well-Tolerated: Trombola 50 mg is generally well-tolerated, with a safety profile that supports its use in long-term treatment under proper medical supervision.

Supplier: Orio Pharma

Orio Pharma ensures that Trombola 50 mg is readily available to healthcare providers and patients, offering reliable access to this essential treatment for thrombocytopenia and aplastic anemia. Their commitment to efficient supply and distribution supports effective management of these conditions, helping to improve patient outcomes and quality of life.

Conclusion:

Trombola 50 mg (Eltrombopag Olamine) by Ziska Pharmaceuticals Ltd, supplied by Orio Pharma, represents a significant advancement in the treatment of chronic immune thrombocytopenia and severe aplastic anemia. This targeted therapy offers an effective and convenient option for managing low platelet counts, reducing the risk of bleeding, and improving the overall health of patients with these challenging conditions. By incorporating Trombola 50 mg into their treatment plans, healthcare providers can offer patients a reliable and effective strategy for managing thrombocytopenia and aplastic anemia, ultimately leading to better health outcomes and enhanced quality of life.